GlassScriptPhysician profile
Allison Frank
NPI 1437719861
$2,144.93
in general payments reported to CMS, 2019-2025
34 companies · $2,145 in 2025
The $2,145 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,144.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $293.24 | 2025 | Imfinzi, Calquence, Tagrisso |
| Agios Pharmaceuticals, INC. | $184.69 | 2025 | Pyrukynd |
| Genmab U.S., INC. | $147.33 | 2025 | Epkinly |
| Gilead Sciences, INC. | $134.32 | 2025 | Trodelvy |
| Pfizer INC. | $115.72 | 2025 | |
| Merck Sharp & Dohme LLC | $113.81 | 2025 | Keytruda |
| Celgene Corporation | $109.45 | 2025 | Reblozyl |
| Novartis Pharmaceuticals Corporation | $98.93 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.04 | 2025 | Iclusig, Fruzaqla, Ninlaro |
| E.R. Squibb & Sons, L.L.C. | $75.79 | 2025 | Opdivo |
| Jazz Pharmaceuticals INC. | $67.47 | 2025 | |
| Janssen Biotech, INC. | $57.71 | 2025 | Rybrevant |
| Lilly USA, LLC | $55.92 | 2025 | Jaypirca, Verzenio |
| Incyte Corporation | $55.02 | 2025 | Jakafi, Monjuvi |
| Genentech USA, INC. | $51.54 | 2025 | Venclexta, Polivy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $50.35 | 2025 | Tevimbra, Brukinsa |
| Deciphera Pharmaceuticals INC. | $34.83 | 2025 | Romvimza, Qinlock |
| Invivyd INC | $30.57 | 2025 | Pemgarda |
| Legend Biotech USA INC. | $30.51 | 2025 | Carvykti |
| Glaxosmithkline, LLC. | $29.35 | 2025 | Ojjaara |
| Puma Biotechnology, INC. | $28.45 | 2025 | |
| Genzyme Corporation | $28.20 | 2025 | |
| Pharmaessentia USA Corporation | $26.74 | 2025 | Besremi |
| Rigel Pharmaceuticals, INC. | $26.01 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Tersera Therapeutics LLC | $23.68 | 2025 | Xermelo |
| Sobi, INC | $23.31 | 2025 | |
| Acrotech Biopharma INC. | $22.93 | 2025 | Beleodaq |
| Daiichi Sankyo INC. | $21.25 | 2025 | Enhertu |
| Abbvie INC. | $20.76 | 2025 | |
| Kite Pharma, INC. | $20.73 | 2025 | Yescarta |
| Coherus Oncology, INC. | $20.00 | 2025 | Loqtorzi |
| Napo Pharmaceuticals INC | $17.86 | 2025 | Gelclair Concentrated Oral Gel |
| Syndax Pharmaceuticals, INC. | $16.71 | 2025 | |
| Springworks Therapeutics, INC. | $14.71 | 2025 | Ogsiveo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.